CAM
ADVM

Cormorant Asset Management’s Adverum Biotechnologies ADVM Stock Holding History

Cormorant Asset Management’s Portfolio ADVM Stock Details ADVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-6,500
Closed -$3.51M – 72
2014
Q4 		$3.51M Hold
6,500
– – 0.54% 44
2014
Q3 		$2.22M Buy
+6,500
New +$1.93M 0.46% 47

Other funds holding ADVM

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
KL
Kam Lawrence $97.4M AUM
SFI
Sonic Fund II Honolulu, Hawaii $147M AUM 19.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Cormorant Asset Management's ADVM Position: Q1 2015 in Review

Cormorant Asset Management sold out of Adverum Biotechnologies (ADVM) in Q1 2015, closing a stake of 6,500 shares — an estimated $3.51M sold.

Cormorant Asset Management first reported a position in ADVM in Q3 2014 and held it in 2 quarters. The position peaked at $3.51M in Q4 2014. 113 funds tracked by Wall St. Rank hold ADVM as of Q1 2015.

  • Cormorant Asset Management reported no remaining Adverum Biotechnologies position as of Q1 2015 after selling out during the quarter.
  • Cormorant Asset Management sold 6,500 Adverum Biotechnologies shares in Q1 2015, an estimated $3.51M.
  • Cormorant Asset Management first reported a position in Adverum Biotechnologies in Q3 2014 and held it in 2 quarters.
  • Cormorant Asset Management's Adverum Biotechnologies position peaked at $3.51M in Q4 2014.
  • 113 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q1 2015.

Based on Cormorant Asset Management's 13F filing for Q1 2015, filed 15 May 2015.